PT2257309T - Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos - Google Patents

Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos

Info

Publication number
PT2257309T
PT2257309T PT97141915T PT09714191T PT2257309T PT 2257309 T PT2257309 T PT 2257309T PT 97141915 T PT97141915 T PT 97141915T PT 09714191 T PT09714191 T PT 09714191T PT 2257309 T PT2257309 T PT 2257309T
Authority
PT
Portugal
Prior art keywords
bacterio
rgd
imaging
photodynamic therapy
necrotic tumors
Prior art date
Application number
PT97141915T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Yeda Res And Development Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res And Development Company Ltd filed Critical Yeda Res And Development Company Ltd
Publication of PT2257309T publication Critical patent/PT2257309T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036Porphyrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0451Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT97141915T 2008-02-27 2009-03-01 Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos PT2257309T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6429808P 2008-02-27 2008-02-27

Publications (1)

Publication Number Publication Date
PT2257309T true PT2257309T (pt) 2020-01-22

Family

ID=40677556

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97141915T PT2257309T (pt) 2008-02-27 2009-03-01 Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos

Country Status (15)

Country Link
US (1) US8815213B2 (enExample)
EP (2) EP2712627A3 (enExample)
JP (1) JP5620279B2 (enExample)
KR (1) KR101595138B1 (enExample)
CN (1) CN102036684B (enExample)
AU (1) AU2009219682B2 (enExample)
BR (1) BRPI0907791A2 (enExample)
CA (1) CA2717060C (enExample)
DK (1) DK2257309T3 (enExample)
ES (1) ES2764781T3 (enExample)
MX (1) MX2010009530A (enExample)
PT (1) PT2257309T (enExample)
RU (1) RU2518296C2 (enExample)
WO (1) WO2009107139A1 (enExample)
ZA (1) ZA201006789B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006331910B2 (en) 2005-12-16 2012-11-29 Amit Shachaf Diagnostic system for the detection and diagnosis of skin cancer
US9957293B2 (en) * 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2011020107A2 (en) * 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
KR101253709B1 (ko) * 2011-06-02 2013-04-12 경북대학교 산학협력단 분비형 표적 추적 융합 단백질
HUE032791T2 (en) 2011-09-05 2017-11-28 Hiroshi Maeda Polymer-type fluorescent molecule probe
US9798856B2 (en) * 2012-03-21 2017-10-24 Koninklijke Philips N.V. Clinical workstation integrating medical imaging and biopsy data and methods using same
CN103705532B (zh) * 2012-10-08 2016-09-14 浙江海正药业股份有限公司 靶向胸苷激酶光敏剂及其药物组合物与治疗癌症的用途
CA2950299A1 (en) 2014-06-02 2015-12-10 Li-Cor, Inc. Phthalocyanine probes and uses thereof
CN106470705B (zh) 2014-08-08 2020-03-31 美国政府(由卫生和人类服务部的部长所代表) 在体内和在体外的靶标的光控移除
HUE054526T2 (hu) 2014-10-29 2021-09-28 Bicyclerd Ltd MT1-MMP-ra specifikus biciklusos peptid ligandumok
WO2016090471A1 (en) * 2014-12-08 2016-06-16 University Health Network System and method for enhanced mass spectrometry imaging
EP3233133B1 (en) 2014-12-19 2020-09-02 Bracco Imaging S.p.A Intra-operative imaging
TWI702259B (zh) * 2015-06-03 2020-08-21 法商瑟吉麥博股份公司 螢光綴合物
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
US11266383B2 (en) 2015-09-22 2022-03-08 University Health Network System and method for optimized mass spectrometry analysis
WO2018115204A1 (en) * 2016-12-23 2018-06-28 Bicycletx Limited Peptide ligands for binding to mt1-mmp
US11730819B2 (en) * 2016-12-23 2023-08-22 Bicycletx Limited Peptide derivatives having novel linkage structures
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
EP3661948B1 (en) 2017-08-04 2022-06-01 BicycleTx Limited Bicyclic peptide ligands specific for cd137
US12478677B2 (en) 2017-08-08 2025-11-25 Board Of Trustees Of Michigan State University Tunable luminescent organic salts for enhanced imaging and photodynamic therapy
JP6920931B2 (ja) * 2017-09-01 2021-08-18 富士フイルム株式会社 医療画像処理装置、内視鏡装置、診断支援装置、及び、医療業務支援装置
SG11202007678QA (en) 2018-02-23 2020-09-29 Bicycletx Ltd Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
RU2700407C1 (ru) * 2018-07-23 2019-09-16 Михаил Тимофеевич Александров Способ лечения опухолевых и воспалительных заболеваний с применением фотодинамической терапии
CN111171030B (zh) * 2018-11-12 2022-11-22 浙江海正药业股份有限公司 细菌叶绿素衍生物及其制备方法
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Pd-l1に特異的な二環式ペプチドリガンド
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4070098B1 (en) * 2019-12-05 2025-12-24 Tempus AI, Inc. Large scale organoid analysis
CN112933252A (zh) * 2021-01-28 2021-06-11 厦门大学附属翔安医院 一种乳腺癌特异靶向分子探针及其制备方法和应用
CN115466311A (zh) * 2021-06-10 2022-12-13 首都医科大学 抗粘附迁移和侵袭的18β-甘草次酸-RGDK,其合成,抗癌转移活性和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121876A1 (de) 1991-07-02 1993-01-14 Scheer Hugo Modifizierte bakteriochlorophylle, verfahren zu ihrer herstellung und ihre verwendung
JPH07503944A (ja) 1991-11-22 1995-04-27 イエダ リサーチ アンド デベロツプメント カンパニー リミテツド Arg−gly−asp配列の非ペプチド代替物およびそれらからなる医薬組成物
IL102645A (en) 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US6147195A (en) 1993-07-26 2000-11-14 Yeda Research And Development Co., Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
IL116126A0 (en) 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
DE69734887T2 (de) * 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
DE19756773A1 (de) * 1997-12-19 1999-06-24 Dade Behring Marburg Gmbh Neues Verfahren und Diagnosemittel zur Hämostase-Diagnostik
PL201172B1 (pl) 1998-12-09 2009-03-31 Yeda Res & Dev Pd-Bakteriofeoforbid, sposób jego wytwarzania, kompozycja farmaceutyczna zawierająca go i jego zastosowanie
US7045117B2 (en) 1999-12-01 2006-05-16 Yeda Research And Development Co. Ltd. Method for tumor diagnosis comprising administering of palladium-substituted bacteriochlorophyll derivatives
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
ES2602460T3 (es) 2004-06-07 2017-02-21 Yeda Research And Development Co., Ltd. Derivados de bacterioclorofila catiónicos y usos de los mismos
CA2650574A1 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
DK2061512T3 (da) 2006-08-23 2020-01-20 Yeda Res & Dev Konjugater af rgd-peptider og (bakterie)chlorophylfotosensibilisatorer samt anvendelser deraf
US20110223102A1 (en) * 2007-09-14 2011-09-15 Health Research, Inc. Multimodality agents for tumor imaging and therapy

Also Published As

Publication number Publication date
DK2257309T3 (da) 2020-01-20
WO2009107139A1 (en) 2009-09-03
US8815213B2 (en) 2014-08-26
AU2009219682B2 (en) 2015-06-18
MX2010009530A (es) 2010-11-30
ZA201006789B (en) 2012-01-25
KR20100127798A (ko) 2010-12-06
EP2712627A3 (en) 2014-04-16
AU2009219682A1 (en) 2009-09-03
RU2010139461A (ru) 2012-04-10
RU2518296C2 (ru) 2014-06-10
BRPI0907791A2 (pt) 2015-08-04
EP2712627A2 (en) 2014-04-02
EP2257309A1 (en) 2010-12-08
US20110064658A1 (en) 2011-03-17
ES2764781T3 (es) 2020-06-04
KR101595138B1 (ko) 2016-02-18
CA2717060A1 (en) 2009-09-03
CA2717060C (en) 2016-11-01
CN102036684A (zh) 2011-04-27
JP2011513298A (ja) 2011-04-28
JP5620279B2 (ja) 2014-11-05
CN102036684B (zh) 2017-06-09
EP2257309B1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
ZA201006789B (en) Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors
GB2466089B (en) Apparatus for photodynamic therapy and photodetection
IL216913A0 (en) Targeted nano-photomedicines for photodynamic therapy of cancer
IL209410A (en) Device for patient placement for cancer treatment using charged particles
EP2280765A4 (en) Treatment of patient tumors by charged particle therapy
IL213070A0 (en) Methods for the treatment of infections and tumors
LT3778885T (lt) Dirbtinai sukurtų žmogaus arginazių kompozicijos ir vėžio gydymo metodai
BRPI0821779A2 (pt) tratamento terapêutico de câncer
GB0700560D0 (en) Device and method for the treatment of diseased tissue such as tumours
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
IL219073A (en) A drug combination for cancer treatment
LT2959900T (lt) Junginys, skirtas vėžio gydymui
PL2616065T3 (pl) GLIKO-PODSTAWIONE DIHYDROKSYCHLORYNY I ß-FUNKCJONALIZOWANE CHLORYNY DO PRZECIWDROBNOUSTROJOWEJ TERAPII FOTODYNAMICZNEJ
IL199682A0 (en) Formulations for cancer treatment
ZA200907492B (en) Compositions for targeted imaging and therapy
IL236516A0 (en) Methods and compositions for diagnosis and treatment of cancer
SI2155248T1 (sl) Ciljanje ABCB5 za zdravljenje raka
PT2054066E (pt) Métodos para tratamento de enterite por radiação
IL200525A0 (en) Methods of treating cancer by administering human il-18 combinations
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
PL2619331T3 (pl) Sposoby leczenia nowotworu obejmujące ukierunkowanie na nqo1
WO2011130486A9 (en) Combination treatments and formulations for cancer
PL385972A1 (pl) Kompozycja farmaceutyczna do leczenia chorób przyzębia
IL207795A0 (en) Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors